Protalix BioTherapeutics Reports Third Quarter 2026 Financial and Business Results
Protalix reported Q3 2026 revenue of $21.9 million, up ~23% year-over-year, with net income of $4.0 million ($0.05 per share) versus $2.4 million a year ago. Year-to-date revenue reached $75.6 million versus $43.6 million, driven largely by a $25.0 million Chiesi milestone tied to the EU approval of Elfabrio's every-four-weeks dosing; goods revenue also rose on higher Chiesi sales, partially offset by lower Pfizer and Fiocruz purchases. Management reaffirmed 2026 guidance of $78-83 million in total revenues and said it expects to meet or exceed the range, ending September with $48.5 million in cash and deposits and no debt or warrants.
Key figures
- Eps
- 0.05
- Revenue
- 75571000
- Guidance
- 2026 total revenues of approximately $78.0 million to $83.0 million, expects to meet or exceed; Elfabrio ex-milestone ~$33.0-35.0M; Elelyso ~$20.0-23.0M
- Revenue Yoy
- 73% (YTD, boosted by $25M milestone; Q3 $21.9M vs $17.9M, +23%)
- Q3 revenue
- 21925000
- Eps ytd basic
- 0.33
- Net income q3
- 3961000
- Net income ytd
- 26055000
- Operating income ytd
- 29865000
- Q3 revenue prior year
- 17851000
- Chiesi milestone q1 2026
- 25000000
- Net income q3 prior year
- 2355000
- Cash and short term deposits
- 48500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.